130 results
8-K
EX-3.2
INBX
Inhibrx Biosciences, Inc.
30 May 24
Termination of a Material Definitive Agreement
4:13pm
of such business as may properly come before the meeting or for any other purpose or purposes may be called by order of the Board of Directors … at such meeting not less than 10 nor more than 60 days prior to the meeting. Notice of any special meeting shall state in general terms the purpose or purposes
8-K
EX-3.1
INBX
Inhibrx Biosciences, Inc.
30 May 24
Termination of a Material Definitive Agreement
4:13pm
.
THIRD: The purpose of the Corporation is to engage in any and all lawful acts or activities for which corporations may be organized under the DGCL
8-K
EX-99.1
INBX
Inhibrx Biosciences, Inc.
24 May 24
Inhibrx Inc. Stockholders Approve Sale of INBRX-101 to Sanofi
4:08pm
. For more information, please visit www.inhibrx.com.
About Sanofi
Sanofi is an innovative global healthcare company, driven by one purpose: chase
8-K
EX-99.1
INBX
Inhibrx Biosciences, Inc.
8 May 24
Other Events
4:42pm
information, please visit www.inhibrx.com.
About Sanofi
Sanofi is an innovative global healthcare company, driven by one purpose: chase the miracles
DEFM14A
0nhzmuda85im36x
26 Apr 24
Proxy related to merger
4:06pm
PREM14A
f146e
29 Feb 24
Preliminary proxy related to merger
5:26pm
DEFA14A
rqrc3
23 Jan 24
Additional proxy soliciting materials
6:38am
8-K
EX-99.1
2cxjeg 1gc5vigep8fm
23 Jan 24
Inhibrx Announces Sale of INBRX-101 to Sanofi for an aggregate value of up to $2.2B
6:35am
8-K
EX-2.1
4q9iaqqw
23 Jan 24
Inhibrx Announces Sale of INBRX-101 to Sanofi for an aggregate value of up to $2.2B
6:35am
8-K
EX-2.2
vjg9b9
23 Jan 24
Inhibrx Announces Sale of INBRX-101 to Sanofi for an aggregate value of up to $2.2B
6:35am
8-K
EX-10.1
2lumau9qrk
29 Aug 23
Inhibrx Announces $200 Million Private Placement Financing
9:03am
8-K
EX-4.1
l7cs3xrxnvhpnavipcv
29 Aug 23
Inhibrx Announces $200 Million Private Placement Financing
9:03am